Advances in CBFA2T3::GLIS2 fusion gene in pediatric acute myeloid leukemia: from molecular mechanisms to targeted therapeutic strategies
Annals of Hematology · 13.08.2026 · 105 (12)
DOI: 10.1007/s00277-026-07227-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Annals of Hematology, online erschienen am 13.08.2026. Verfasst von Jiatong She und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Children Hematological Oncology, Children Hematological Oncology and Birth Defects Laboratory, Sichuan Clinical Research Center for Bir…. Hauptthemen laut MEDLINE: Oncogene Proteins, Fusion, Leukemia, Myeloid, Acute, Molecular Targeted Therapy. Die Arbeit nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sichuan Provincial Science and Technology Support Program, the key project of Southwest Medical University clinical medicine special program.
Abstract (Originalsprache)
Acute myeloid leukemia (AML) is a genetically heterogeneous hematologic malignancy in children, with molecular alterations playing critical roles in disease development and therapeutic responses. The CBFA2T3::GLIS2 (C/G) is the most frequent genetic alteration identified in non-Down syndrome acute megakaryoblastic leukemia (AMKL) and results from a cryptic inversion involving the subtelomeric region of chromosome 16. Multiple chimeric transcripts can be generated depending on the breakpoint location, with CBFA2T3-ex11/GLIS2-ex3 being the predominant transcript. This fusion gene is associated with chemotherapy resistance and an unfavorable clinical outcome. Although initially identified in AMKL, it has also been detected in several cytogenetically normal AML subtypes, including M0, M1, M2, M4, and M5. However, the molecular mechanisms underlying C/G fusion-driven leukemogenesis remain incompletely characterized. This review provides an overview of the pathogenic mechanisms, emerging therapeutic strategies, and clinical challenges associated with C/G-positive pediatric AML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Children Hematological Oncology, Children Hematological Oncology and Birth Defects Laboratory, Sichuan Clinical Research Center for Birth Defects, The Affiliated Hospital of Southwest Medical University, N…
Förderung
- Sichuan Provincial Science and Technology Support Program
- the key project of Southwest Medical University clinical medicine special program
Zitieren
APA
She, J., Guo, L., Yang, Y., Liu, J., Zhang, R., Liu, Y., Guo, H., Huang, Y., & Liu, W. (2026). Advances in CBFA2T3::GLIS2 fusion gene in pediatric acute myeloid leukemia: from molecular mechanisms to targeted therapeutic strategies. Annals of Hematology, 105(12). https://doi.org/10.1007/s00277-026-07227-2
Vancouver
She J, Guo L, Yang Y, Liu J, Zhang R, Liu Y, et al. Advances in CBFA2T3::GLIS2 fusion gene in pediatric acute myeloid leukemia: from molecular mechanisms to targeted therapeutic strategies. Annals of Hematology. 2026;105(12). doi:10.1007/s00277-026-07227-2
BibTeX
@article{She2026,
author = {She, Jiatong and Guo, Ling and Yang, You and Liu, Jing and Zhang, Rui and Liu, Yan and Guo, Huazhang and Huang, Yangyang and Liu, Wenjun},
title = {Advances in CBFA2T3::GLIS2 fusion gene in pediatric acute myeloid leukemia: from molecular mechanisms to targeted therapeutic strategies},
journal = {Annals of Hematology},
year = {2026},
volume = {105},
number = {12},
doi = {10.1007/s00277-026-07227-2}
}
EUVIMED